Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/25/2023 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 5/22/2023 | $31.00 | Buy | CL King |
| 2/24/2022 | $47.00 → $41.00 | Overweight | Keybanc |
| 1/7/2022 | $37.00 → $36.00 | Underweight | Morgan Stanley |
| 8/4/2021 | $45.00 → $41.00 | Underweight | Morgan Stanley |
| 8/4/2021 | $60.00 → $45.00 | Overweight → Equal-Weight | Stephens |
| 8/4/2021 | $55.00 → $47.00 | Overweight | Keybanc |
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m
ALPHARETTA, Ga., Jan. 7, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Dave Pacitti, chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, Jan. 13, at approximately 2:15 p.m. PST. A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site. About Avanos Medical, Inc. Avanos Medical, Inc. (NYSE:AVNS) is a medical technology company focused on delivering clinically superior medical devi
Delivered double-digit growth in Specialty Nutrition Systems segmentClosed acquisition of Nexus Medical, providing a complementary technology for the Specialty Nutrition Systems segmentRaising and narrowing top-line guidance and adjusted EPS guidance for the full yearALPHARETTA, Ga., Nov. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported third quarter 2025 financial results. "I am pleased with our third quarter results, both operationally and commercially," said David Pacitti, Avanos' chief executive officer. Pacitti continued, "Avanos delivered double-di
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
KeyBanc Capital Markets downgraded Avanos Medical from Overweight to Sector Weight
CL King initiated coverage of Avanos Medical with a rating of Buy and set a new price target of $31.00
Keybanc reiterated coverage of Avanos Medical with a rating of Overweight and set a new price target of $41.00 from $47.00 previously
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
3 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
8-K/A - AVANOS MEDICAL, INC. (0001606498) (Filer)
SCHEDULE 13G - AVANOS MEDICAL, INC. (0001606498) (Subject)
10-Q - AVANOS MEDICAL, INC. (0001606498) (Filer)
SC 13G - AVANOS MEDICAL, INC. (0001606498) (Subject)
SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)
SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m
ALPHARETTA, Ga., Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of Scott Galovan as its new senior vice president, chief financial officer, effective Aug. 1, 2025. Galovan most recently served as Avanos' senior vice president of strategy and corporate development. His background with the company spans 12 years and is highlighted by a proven track record of leading a number of acquisition and divestiture initiatives. Prior to Avanos, he spent 10 years in a variety of strategy, finance, and M&A
ALPHARETTA, Ga., June 9, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) a leading medical technology company focused on delivered innovative healthcare solutions, today announced the appointment of Camille Chang Gilmore as senior vice president and chief human resources officer. In this role, Gilmore will lead all aspects of Avanos' people strategy, including talent acquisition and development, workforce planning, leadership development and employee experience. Her arrival reflects the company's continued commitment to building a workplace where every employee feels val
Delivered double-digit growth in Specialty Nutrition Systems segmentClosed acquisition of Nexus Medical, providing a complementary technology for the Specialty Nutrition Systems segmentRaising and narrowing top-line guidance and adjusted EPS guidance for the full yearALPHARETTA, Ga., Nov. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported third quarter 2025 financial results. "I am pleased with our third quarter results, both operationally and commercially," said David Pacitti, Avanos' chief executive officer. Pacitti continued, "Avanos delivered double-di
ALPHARETTA, Ga., Oct. 27, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the second quarter 2025 on Wed., Nov. 5, at 9 a.m. ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Dave Pacitti, chief executive officer, and Scott Galovan, senior vice president and chief financial officer. To instantly join the conference call by phone, use the following link to register close to the call start time:
ALPHARETTA, Ga., Sept. 15, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the acquisition of Nexus Medical, LLC, a privately held medical device company based in Lenexa, Kansas. Nexus is the maker of the proprietary TKO® anti-reflux needleless connector technology, designed to support safer, more consistent nutrition and medication delivery in high-acuity settings, including Neonatal and Pediatric Intensive Care Units (NICUs and PICUs). The acquisition adds complementary technology to Avanos' Specialty Nutrition Sys